BRD4 and myeloid neoplasm: These findings support a role for the ASXL1aa1−587–BRD4 axis in the hematopoietic phenotypes exhibited by Asxl1Y588X transgenic mice and raise the possibility of targeting BRD4 in myeloid malignancies with mutated ASXL1 (Fig. 5) [75].